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Drug toxicity predictionTargeted anticancer drugs such as imatinib, trastuzumab and erlotinib dramatically improved treatment
outcomes in cancer patients, however, these innovative agents are often associated with unexpected side
effects. The pathophysiological mechanisms underlying these side effects are not well understood. The
availability of a comprehensive knowledge base of side effects associated with targeted anticancer drugs
has the potential to illuminate complex pathways underlying toxicities induced by these innovative
drugs. While side effect association knowledge for targeted drugs exists in multiple heterogeneous data
sources, published full-text oncological articles represent an important source of pivotal, investigational,
and even failed trials in a variety of patient populations. In this study, we present an automatic process to
extract targeted anticancer drug-associated side effects (drug–SE pairs) from a large number of high
proﬁle full-text oncological articles.
We downloaded 13,855 full-text articles from the Journal of Oncology (JCO) published between 1983
and 2013. We developed text classiﬁcation, relationship extraction, signaling ﬁltering, and signal
prioritization algorithms to extract drug–SE pairs from downloaded articles. We extracted a total of
26,264 drug–SE pairs with an average precision of 0.405, a recall of 0.899, and an F1 score of 0.465.
We show that side effect knowledge from JCO articles is largely complementary to that from the US
Food and Drug Administration (FDA) drug labels. Through integrative correlation analysis, we show that
targeted drug-associated side effects positively correlate with their gene targets and disease indications.
In conclusion, this unique database that we built from a large number of high-proﬁle oncological articles
could facilitate the development of computational models to understand toxic effects associated with
targeted anticancer drugs.
 2015 Elsevier Inc. All rights reserved.1. Introduction pathway, has been associated with complete to partial responseTargeted anticancer drugs control cancer cell growth by inter-
fering with speciﬁc molecular targets involved in tumor growth
and progression. Targeted cancer therapies have signiﬁcantly
(positively) impacted the survival and quality of life of cancer
patients [1]. For instance, treatment of Philadelphia-positive
chronic myeloid leukemia (CML) with tyrosine kinase inhibitor
(TKI) imatinib confers a signiﬁcant survival advantage and an over-
all 80–90% response rate [2]. Trastuzumab, a monoclonal antibody
that binds to the extracellular domain of HER2, is used to treat
patients with metastatic HER2-positive breast cancer and has
decreased the cancer recurrence risk in treated patients by 52%
and reduced relative risk of mortality by 33% [3]. Erlotinib, a TKI
that induces cancer cell apoptosis by blocking the EGFR signalingand improved overall survival in patients with non-small-cell lung
cancer [4].
Targeted anticancer drugs promised new ways to personalize
cancer treatments based on unique molecular targets expressed
by tumor cells. However, recent studies have shown that these
innovative drugs are often associated with unanticipated high
toxicities [5]. Recent meta-analysis studies show that most
newly-approved targeted anticancer drugs are more toxic than
standard treatments and are associated with increased rates of
toxic death, treatment discontinuation, and severe adverse events
[6,7]. Besides the overall toxicity levels, many targeted anticancer
drugs are associated with unanticipated toxicities, such as cardio-
vascular events, that are idiosyncratic and their underlying
molecular mechanisms remain largely unidentiﬁed [5,8–10].
Unlike side effects induced by cytotoxic chemotherapeutics, which
are similar among drugs, side effects associated with targeted
anticancer drugs often differ among drugs of the same class such
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by the receptor cross-reactivity, the presence of receptors on nor-
mal cells [12], or the multiplicity of affected off-target proteins
[13–15]. In order to maintain the balance between tumor control
and drug-induced toxicities, research is needed to improve our
understanding of the molecular mechanisms of targeted anticancer
drug-related toxicities [1]. Currently, approximately 500 novel
targeted agents are under preclinical or clinical development for
the treatment of speciﬁc types of cancers [16]. The availability of
a comprehensive side effect knowledge base for targeted
drugs and innovative computational approaches to predicting
unexpected toxicities are important for the successful develop-
ment of targeted anticancer agents in the near future.
Current systems approaches to studying phenotypic or side
effect relationships among drugs rely exclusively on information
extracted from the US Food and Drug Administration (FDA) drug
labels [17–21]. It was recently demonstrated that 39% of serious
events associated with targeted cancer drugs are never reported
in clinical trials and 49% are not described in FDA drug labeling
[22]. Therefore, in constructing a comprehensive knowledge base
of drug-side effect (drug–SE) relationships for cancer drugs, it is
important to extract knowledge from multiple sources, including
FDA drug labels, the FDA post-market drug safety surveillance
system (FAERS), patient electronic health records (EHRs), and the
large body of published biomedical literature. Recently, we devel-
oped automatic signal prioritizing and ﬁltering approaches in
detecting post-marketing cardiovascular events associated with
targeted cancer drugs from FAERS [24]. We developed an large-
scale approach to combine signals from both biomedical literature
and FAERS to improve post-marketing drug safety signal detection
[25]. For drug–SE relationship extraction from biomedical litera-
ture abstracts, we developed an automatic approach to extract
anticancer drug-speciﬁc side effects from MEDLINE by developing
speciﬁc ﬁltering and ranking schemes [26]. We also developed a
pattern-based learning approach to accurately extract drug–SE
pairs from MEDLINE sentences [27].
The Journal of Clinical Oncology (JCO) is the ofﬁcial journal of
the American Society of Clinical Oncology and the leading journal
in oncology. JCO articles include a variety of cancer-related
research articles, including clinical trials reporting drug efﬁcacy
and toxicity in cancer patients, trial reports evaluating the effec-
tiveness of biomarkers, clinical case reports, and meta-analysis
studies, among other article types. JCO articles not only include
pivotal clinical trials that have led to drug approval, but also trials
that are still in investigational stages and even failed trials. Side
effect knowledge for both commercial, investigational and failed
drugs is crucial to our understanding of the molecular mechanisms
underlying the observed toxicities. In one of our recently studies,
we downloaded a total of 13,855 full-text JCO articles published
between 1983 and 2013. We combined automatic table classiﬁca-
tion and relationship extraction approaches to extract anticancer
drug-associated side effects from a total of 31,255 tables embed-
ded in these JCO articles. We extracted a total of 26,918 drug–SE
pairs from SE-related tables with a precision of 0.605, a recall of
0.460, and a F1 of 0.520 [28]. Complementary to our previous
study, our current study presents an integrated system combining
text classiﬁcation, relationship extraction, signal ﬁltering, and
signal prioritization algorithms to extract targeted anticancer
drug-associated side effects from the full-text part of JCO articles.
2. Approach
We ﬁrst developed a support vector machine (SVM) classiﬁer to
classify downloaded articles into drug SE-related and -unrelated.
We then extracted drug–SE co-occurrence pairs from articles that
were classiﬁed as SE-related. We developed a ﬁltering approachto remove false positives (drug–disease treatment pairs) from the
extracted drug–SE co-occurrence pairs. We then developed ranking
algorithms to further prioritize extracted drug–SE pairs based on
their term and document frequencies. We investigated whether
the drug side effect knowledge from JCO articles is complementary
to that in FDA drug labeling by exhaustively curating all articles
containing the drug sunitinib in their titles and comparing
drug–SE pairs extracted from these JCO articles to those extracted
from the FDA drug label. To show the potential of these targeted
drug-associated side effects in developing systems approaches to
understanding the molecular mechanisms underlying the observed
drug phenotypes (side effects) and drug repositioning, we linked
drugs to their corresponding gene targets and disease indications
and systematically studied the correlations between targeted
anticancer drug-associated side effects and their known gene
targets and disease indications.
Our study is different from many literature-based drug–SE
relationship extractions [24–26,31] in at least two ways. First, most
literature-based drug–SE relationship extraction tasks used only
the abstracts of biomedical research articles, whilewe used full-text
articles. While full-text articles contain richer drug–SE association
knowledge compared to abstracts, they also contain much noise,
which renders the extraction task more challenging. Second, while
previous studies applied either machine learning approach[30,27]
or speciﬁc signal ﬁltering and ranking approaches [24], we here
combined both approaches in extracting drug–SE pairs from
full-text articles. This study is complementary to our previous study
in extracting drug–SE pairs from tables of JCO articles. In this study,
we used the text part of JCO articles for drug–SE extraction. In
addition, we focus on targeted anticancer drugs. Our main con-
tribution is that we extracted a large number of targeted anticancer
drug-associated side effects from high-proﬁle oncological articles,
the majority of which have not included in FDA drug labeling
yet. In addition, we show that these extracted drug–SE pairs
have the potential to illuminate complex pathways of targeted
drug-induced side effects and to discover novel drug indications.3. Methods
The overall experiment consists of the following steps: (1)
download JCO full-text articles; (2) Classify JCO articles into drug
SE-related and -unrelated; (3) Extract drug–SE pairs from articles
classiﬁed as SE-related; (4) Filter out drug–disease treatment pairs;
(5) Rank ﬁltered pairs; (6) Manually evaluate the performance of
drug–SE pair extraction; (7) Compare the drug–SE knowledge
captured in JCO articles to that in FDA drug labels; and (8)
Analyze the correlations between extracted drug–SE pairs and drug
targets as well as drug disease indications (Fig. 1).
3.1. Download JCO full text articles
In our previous study, we downloaded a total of 13,855 JCO full
text JCO articles published from 1983 through 2013 and extracted
anticancer drug–SE pairs from the tables embedded in the articles
[28]. In this study, we used the text part of these downloaded JCO
articles for targeted anticancer drug–SE relationship extraction.
We used the publicly available information retrieval library
Lucene (http://lucene.apache.org) to create a search engine with
indices created on article titles, abstracts, and all text. Each article
was assigned a unique identiﬁcation number.
3.2. Classify articles into drug SE-related and -unrelated
We randomly selected 500 articles from the 13,855 downloaded
full-text JCO articles and manually classiﬁed them into drug
Fig. 1. Experiment ﬂowchart.
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SE-related and 393 are SE-unrelated. These articles were randomly
split into the training dataset (60%) and testing dataset (40%). An
SVM classiﬁer [34] was trained on the training dataset and tested
on the testing dataset. The SVM-based classiﬁer used polynomial
kernel, bag-of-words feature, TF-IDF weighting, stemming and
stopwords-removal. The bag-of-words feature was used since it
is often the case that the appearance of one speciﬁc word such as
‘toxicity’ or ‘adverse’ can be used to determine whether a sentence
is drug–SE-related. The 10-fold cross validation was used in
training the classiﬁer. When evaluated on the testing dataset, the
classiﬁer achieved a precision of 0.862, a recall of 0.677, a F1 score
of 0.759, a false positive rate of 0.029, and a false negative rate of
0.323.
3.3. Extract drug–SE pairs from classiﬁed JCO articles
The inputs to the drug–SE pair extraction algorithm were a list
of targeted anticancer drugs, a list of SE terms, and JCO articles that
were automatically classiﬁed as SE-related.
3.3.1. Targeted drug lexicon
A list of 45 targeted cancer drugs was obtained from the
National Cancer Institute (NCI).1 The 45 targeted drugs are:
alemtuzumab, litretinoin, anastrozole, bevacizumab, bexarotene,
bortezomib, bosutinib, brentuximab, cabozantinib, carﬁlzomib,
cetuximab, crizotinib, dasatinib, denileukin, erlotinib, everolimus,
exemestane, fulvestrant, geﬁtinib, ibritumomab, imatinib, ipili-
mumab, lapatinib, letrozole, nilotinib, ofatumumab, panitumumab,
pazopanib, pertuzumab, pralatrexate, regorafenib, rituximab, romi-
depsin, sorafenib, sunitinib, tamoxifen, temsirolimus, toremifene,
tositumomab, trastuzumab, tretinoin, vandetanib, vemurafenib,
vorinostat, and ziv-aﬂibercept.
3.3.2. Manually curated clean side effect (SE) lexicons
An accurate and comprehensive SE lexicon is critical for the task
of drug–SE relationship extraction from free-text. We have built
two clean SE (or disease) lexicons and demonstrated that these
clean lexicons are important in improving precisions in biomedical
relationship extraction tasks, including drug–SE relationship
extraction [23–28] and disease–phenotype relationship extrac-
tions [28,30]. The ﬁrst SE lexicon was built based on the Medical
Dictionary for Regulatory Activities (MedDRA) [32] by manually
removing many non-SE terms such as medical procedures, lab
tests, and protein names. After manual curation, the lexicon con-
tained 49,625 terms. The second SE (or disease) lexicon was based
on the Uniﬁed Medical Language System (UMLS) (2011AB version)1 http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.[33] and was built by manually removing incorrectly classiﬁed dis-
ease terms, ambiguous terms, and overly general terms. The ﬁnal
UMLS-based clean lexicon consisted of 75,558 terms. In this study,
we demonstrated that these clean lexicons considerably improved
upon the overall precision of the subsequent drug–SE relationship
extraction from full-text JCO articles.
3.3.3. Drug–SE pair extraction from automatically classiﬁed articles
We then trained a SVM classiﬁer using these 500 annotated
articles and used it to classify all 13,855 JCO articles. A total of
2602 articles are classiﬁed as SE-related. We used each targeted
anticancer drug as a search query to the local search engine. If a
drug term appeared in the title or text of an SE-related article,
the term, its frequency, and the article ID was recorded.
Similarly, we used each term from the clean SE lexicons as a search
query to the local search engine. If a SE term appeared in the title
or text of an article, the term, its frequency, and the article ID was
recorded. Drug–SE pairs, along with their document frequency and
term frequency, were extracted by joining the article IDs asso-
ciated with drug terms and with SE terms.
3.4. Filter extracted drug–SE pairs by removing drug–disease (cancer)
treatment pairs
Drug-associated side effects are often reported in the context of
drug treatments in patients with cancers. Therefore, one of the
main challenges in extracting drug–SE pairs from JCO articles is
to differentiate drug–SE causal pairs from drug–disease treatment
pairs. This task is made easier by the fact that we can in general
classify the extracted pairs into causal or treatment relationship
based on the medical condition entities (the SE terms) alone. If
the SE term in a drug–SE pair is a cancer term, then this pair is
more likely to be a drug–disease treatment pair than a drug–SE
causal pair (though some drugs also cause cancers). In this study,
we ﬁrst removed many cancer terms from the SE lexicons by ﬁlter-
ing out terms of the semantic type ‘‘Neoplastic Process’’ based on
UMLS classiﬁcation. We then extracted drug–SE pairs using these
ﬁltered SE lexicons. We showed that this ﬁltering strategy removed
many false positives and signiﬁcantly improved the precision
while keeping the high recall of the extracted drug–SE pairs.
3.5. Rank ﬁltered drug–SE pairs based on term and document
frequency
We developed two ranking algorithms to rank the ﬁltered drug–
SE pairs. The ﬁrst one is to rank drug–SE pairs according to their
total occurrences in the entire corpus, which is equivalent to the
term frequency used in information retrieval. The second one is
to rank drug–SE pairs according to their document frequencies
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that if a drug–SE pair appears often in many different articles, then
it is likely that there is a true semantic association between the
drug and the SE entity. This semantic association can be ‘‘DRUG
cause SE’’ or ‘‘DRUG treat DISEASE.’’ Since we have already ﬁltered
out the drug–disease treatment pairs, then the top-ranked pairs
are more likely to be drug–SE causal pairs. We measured the rank-
ing efﬁcacy using 11-point interpolated average precision, which is
commonly used to evaluate retrieved ranked lists for search
engines [35]. For each ranked list, the interpolated precision was
measured at the 11 recall levels of 0.0, 0.1, 0.2, . . . , 1.0. A composite
precision–recall curve showing 11 points was then graphed and
used to evaluate whether the ranking algorithms work effectively
in prioritizing extracted drug–SE pairs.
3.6. Manual evaluation
Currently, there exists no gold standard that accurately
represents drug-associated side effect knowledge captured in JCO
articles. For example, as we will show later in this study, many
of drug–SE pairs for FDA-approved drugs were reported in JCO
articles but not included in FDA drug labels yet; therefore,
drug–SE pairs derived from FDA drug labels cannot serve as a gold
standard to evaluate drug–SE relationship extraction from JCO
articles. In addition, JCO articles also include many investigational
drugs and failed drugs while FDA drug labels contain only
commercial drugs. In this study, we ﬁrst classiﬁed all articles into
SE-related or -unrelated. We then automatically annotated all
SE-related articles using drug and SE terms from the input lexicons
as search queries. We then randomly selected 100 SE-related
articles with titles containing one targeted anticancer drug term.
We then manually extracted drug–SE pairs from these articles.
Three curators with graduate degrees in biomedical sciences or
clinical medicines independently performed the manual curation.
It took approximate 24 h for each annotator to curate these 100
articles. The inter-annotator agreement rate was 85%. For each
article, only drug–SE pairs agreed upon by all three curators were
used as the gold standard. We ran our algorithm on these articles
and calculated precision, recall, and F1 for each article using the
manually curated pairs from these articles as goldstandard. The
ﬁnal reported precision, recall, and F1 were averages of precisions,
recalls and F1s across these 100 articles.
3.7. Compare side effect knowledge extracted from JCO articles to that
from FDA drug label
We investigated whether the drug side effect knowledge from
JCO articles is complementary to that in FDA drug labeling. We
exhaustively curated all 49 articles that contain the targeted drug
sunitinib in their titles. We then compared drug–SE pairs extracted
from these 49 JCO articles to those extracted from its FDA drug
label. Sunitinib is a multi-targeted receptor tyrosine kinase inhibi-
tor approved for the treatment of renal cell carcinoma and gas-
trointestinal stromal tumor. Since sunitinib targets multiple
receptors that are involved in both tumor growth and normal cell
functions, it is associated with many different types of side effects.
From the 49 JCO articles, we manually extracted 332 sunitinib–SE
pairs. From the FDA drug label that we downloaded,2 we manually
extracted a total of 117 sunitinib–SE pairs. We compare]d the over-
lap of sunitinib–SE pairs between these two sources. In addition, we
also compared the overlap of sunitinib–SE pairs between these two
sources at difference frequency cutoffs in order to investigate2 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43a4d7f8-48ae-4a63-
9108-2fa8e3ea9d9c. 3 www.clinicaltrials.gov.whether more frequently reported pairs in JCO articles tend to be
more likely captured in FDA drug labels.3.8. Analyze drug–SE pairs
We investigated whether drug–drug pairs that shared side
effects also tended to share gene targets and disease indications.
We downloaded a total of 10,478 drug–gene pairs from
DrugBank [36], a knowledge base for drugs, drug actions, and drug
targets. These downloaded drug–gene pairs included a total of 24
targeted cancer drugs. For drug–drug pairs that shared different
numbers of side effects, we calculated the average number of
shared gene targets.
We extracted a total of 52,000 drug–disease pairs from
ClinicalTrials.gov, a registry of federally- and privately-supported
clinical trials conducted in the United States and around the
world.3 For drug–drug pairs that shared SEs at different cutoffs, we
calculated the average number of shared disease indications.4. Results
4.1. Performance of drug–SE relationship extraction from JCO full text
articles
To measure the performance of the relationship extraction algo-
rithm, we applied the algorithm to the 100 evaluation articles. For
each article, we calculated the precision, recall, and F1 using the
manually-extracted pairs from the same article as the gold stan-
dard. We then calculated the average precision, recall, and F1 of
the algorithm across these 100 articles. We compared the perfor-
mance of the algorithm using different SE lexicons (clean vs. origi-
nal, separate vs. combined, cancer-ﬁltered vs. unﬁltered). These SE
lexicons included (1) three MedDRA-based SE lexicons: original,
clean, and clean lexicon with all cancer terms removed (‘‘Clean
minus cancer terms’’); (2) three UMLS-based SE lexicon: original,
clean, and clean lexicon with all cancer terms removed (‘‘Clean
minus cancer terms’’); and (3) a combined clean lexicon consisted
of terms from both MedDRA and UMLS, also with cancer terms
removed. The drug lexicon was consisted of 45 targeted cancer
drug terms obtained from NCI. The overall recalls of the algorithm
were high, ranging from 0.708 to 0.899, meaning that the SE lexi-
cons covered the majority of the SE concepts used in JCO articles
(Table 1). However, the precisions varied greatly from 0.075 to
0.405.
Comparing the clean SE lexicons with the original lexicons, we
show that the precision signiﬁcantly increased from 0.112 to 0.230
for the MedDRA-based SE lexicon, and from 0.075 to 0.165 for the
UMLS-based SE lexicon. The MedDRA-based SE lexicon also had a
better precision than the UMLS-based SE lexicon. Comparing the
clean SE lexicons with the same lexicons removed of cancer
terms, we showed that the precisions further signiﬁcantly
increased from 0.230 to 0.405 for the MedDRA-based SE lexicon,
as well as increasing from 0.165 to 0.310 for the UMLS-based SE
lexicon. By combining terms from two clean lexicons, we did not
observe improvements in precision or recall.
The precisions, recalls, and F1 values varied greatly across dif-
ferent articles. As shown the Fig. 2, the recalls were consistently
high, ranging from 0.67 to 1.0. However, the precisions and F1
values varied greatly from 0.0 to 1.0. Several factors may have
contributed to the varying precisions. First, the text classiﬁer
(precision: 0.862, recall: 0.677, F1: 0.759) is not perfect in classify-
ing articles into SE-related and -unrelated. Many SE-unrelated JCO
articles such as those evaluating biomarkers in predicting the
Table 1
Table classiﬁcation performance. Classiﬁcation on tables containing SE terms from
manually curated MedDRA lexicon with cancer terms removed (‘‘Clean minus cancer
terms’’) performed best.
SE lexicon Lexicon processing Precision Recall F1
MedDRA Original 0.112 0.891 0.176
Clean 0.230 0.886 0.303
Clean minus cancer terms 0.405 0.899 0.465
UMLS Original 0.075 0.708 0.118
Clean 0.165 0.714 0.218
Clean minus cancer terms 0.310 0.712 0.337
Combined Clean minus cancer terms 0.310 0.878 0.380
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describing patient co-morbidities, outcomes measures, for
instance); however, these disease terms are not drug-associated
side effects. Second, even in SE-related clinical trial articles that
report drug efﬁcacy and toxicities, disease terms are often con-
tained in the patient inclusion and exclusion criteria sections. ForFig. 2. Precisions, recalls and F1 values across the evaluation data
Fig. 3. Precision–recall curves for drug–SE pairs rankeexample, some studies may exclude patients with renal insufﬁ-
ciency or cardiovascular diseases. A potential way to avoid extract-
ing pairs from these sections is to develop a nested classiﬁer to
further categorize sections or sentences in SE-related articles into
toxicity-related or -unrelated.4.2. Ranking by both term frequency and document frequency further
improve the precisions
In the previous section, we show that we signiﬁcantly improved
the precision of drug–SE extraction from 0.112 to 0.405 by using
manually-curated SE lexicons and by ﬁltering out cancer terms
from the clean SE lexicons. In this section, we developed a ranking
algorithm to further prioritize the extracted drug–SE pairs. We
ranked the ﬁltered drug–SE pairs by term frequency and by docu-
ment frequency. As shown in Fig. 3, ranking by both term fre-
quency and document frequency are effective in ranking true
positives highly. For example, for pairs ranked by documentset of 100 randomly selected and manually curated articles.
d by term frequency and by document frequency.
Fig. 4. Percentages of top ranked sunitinib–SE pairs extracted from JCO articles that are included in FDA drug label.
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of 0.957, representing a signiﬁcant elevation in precision as
compared to the overall precision of 0.405 for the whole list (at a
recall of 1.0). Ranking by term frequency and by document
frequency had similar results, even though the top-ranked pairs
by document frequency had slightly higher precisions.
4.3. Comparison of toxicity knowledge contained in JCO articles to that
in FDA drug labels
In this section, we investigated whether the drug side effect
knowledge contained in JCO articles is complementary to that in
FDA drug labeling. Side effect information from FDA drug labels
is mainly derived from pivotal clinical trials or post-marketing
experience of patients with the same diseases. Notably, the side
effect information reported in JCO articles includes not only pivotal
clinical trials, but also investigational and even failed trials in
patients with the same or different cancers. For example, between
April 2009 and May 2011, Pﬁzer has reported unsuccessful late-
stage trials in using sunitinib in the treatment of breast cancer,
metastatic colorectal cancer, advanced non-small-cell lung cancer,
and castration-resistant prostate cancer.
From the 49 JCO articles (unclassiﬁed) containing drug term
sunitinib, we manually extracted a total of 332 sunitinib–SE pairs,
with each pair assigned a frequency count (number of times a pair
appeared in these 49 articles). From the FDA drug label for sunitinib,
wemanually extracted a total of 117 side effects. Among these pairs,
only 53 pairs, representing 15.8% of pairs extracted from JCO articles
and 44.8% of pairs from FDA drug labels, appeared in both sources.
This indicates that the drug side effect knowledge from these two
resources has some overlap but is largely complementary.
We then ranked the drug–SE pairs extracted from JCO articles
by their term frequencies and investigated where frequent pairs
were more likely to be included in both sources. We calculated
the percentages of the top-ranked pairs extracted from JCO articles
that were included in FDA drug labels. As shown in Fig. 4,
top-ranked (frequent pairs) drug–SE pair were more likely to be
included in FDA drug labeling than less frequent pairs. For exam-
ple, among the top 10% of ranked pairs extracted from JCO articles,
62.5% of them were also included in FDA drug labeling. The
number steadily deceased to 40.3% for top the 20% of ranked pairs
and to 25% for the top 40% of ranked pairs.
Many rare and severe adverse events associated with targeted
drugs in cancer patients were reported in JCO articles but notincluded in FDA drug labeling. For example, in a case report article
published in 2012 entitled ‘‘Takotsubo Syndrome in a Patient
Treated With Sunitinib for Renal Cancer’’ reported that takotsubo
syndrome was associated with sunitinib in patients with renal
cancer. However, this association has not included in FDA drug
labeling for sunitinib yet. In another article published in 2010
entitled ‘‘Recurrent Scrotal Hemangiomas During Treatment With
Sunitinib’’ reported an instance of recurrent scrotal cutaneous
capillary hemangiomas developed during therapy with sunitinib
in a patient with renal cell carcinoma, and discussed a possible
histopathogenetic mechanism of sunitinib. This adverse event is
not included in drug labeling for sunitinib yet. Two other examples
are acute myeloblastic leukemia and thyrotoxicosis that are
reported to be associated with sunitinib in articles entitled
‘‘Phase II Study of Sunitinib Administered in a Continuous Once-
Daily Dosing Regimen in Patients With Cytokine-Refractory
Metastatic Renal Cell Carcinoma’’ and ‘‘Thyrotoxicosis during
sunitinib treatment for renal cell carcinoma,’’ respectively.
4.4. Targeted cancer drug-associated side effects correlate positively
with their target genes and disease indications
Drug-associated side effects may be caused by both drug ‘on-
target’ and ‘off-target’ effects. In this section, we investigated the
degree of targeted drug-associated side effects being correlated
to their known drug-associated gene targets. We also investigated
whether the observed drug side effects are correlated with drug
indications, which may have implications in drug repositioning.
Among the 45 targeted drugs from the extracted 26,264 drug–
SE pairs, 24 drugs have known associated target genes based on
drug–gene association data from DrugBank. For all 276 drug–drug
combinations for these 24 drugs (shared SEsP 0), the average
number of shared gene targets is 1.678. The number increases as
drug–drug pairs sharing more SEs. The average number of shared
gene targets is 2.081 for the 186 drug-drug pairs that shared at
least 200 SEs, and the average number of shared gene targets is
2.278 for 115 pairs that shared at least 300 SEs (Fig. 5). This
demonstrates that some shared SEs among targeted anticancer
drugs belongs to on-target effects and caused by their effects on
normal cells. However, the modest positive correlation between
shared SEs and shared ‘on-target’ genes indicates that many tar-
geted drug-associated side effects may be caused by factors other
than drug ‘on-targets’, such as unknown ‘off-targets,’ drug metabo-
lism, patient-speciﬁc characteristics including co-morbidities and
performance status, and drug combinations or co-occurrent drugs.
Fig. 5. The correlation between drug side effects and drug targets.
Fig. 6. The correlation between drug side effects and drug disease indications.
70 R. Xu, Q. Wang / Journal of Biomedical Informatics 55 (2015) 64–72We investigated whether the observed drug side effects corre-
late with drug disease indications. A positive correlation implies
that we may use the observed drug phenotype information in drug
repositioning tasks. A total of 36 out of 45 targeted cancer drugs
appeared in ClinicalTrial.gov. Note that many studies registered
in ClinicalTrial.gov are still in investigational stages. As shown in
Fig. 6, there is a strong positive correlation between shared SEs
and shared disease indications. The average number of shared
disease indications for all 630 drug–drug combinations was
15.07. The number signiﬁcantly increased to 22.61 for 333 drug–
drug pairs that shared at least 200 SEs and to 33.59 for 114
drug-drug pairs that shared at least 400 SEs. The correlation of side
effects with drug indications (Fig. 6) is stronger than that with drug
targets (Fig. 5). These results indicate that we can leverage upon
targeted drug-associated side effects for drug repositioning, even
though we do not understand the pathophysiology underlying
many these observed drug clinical phenotypes.
5. Discussion
In this study, we developed automatic relationship extraction,
signal ﬁltering, and ranking approaches to constructing a largescale drug–SE relationship knowledge base for targeted anticancer
drugs from 13,855 full-text articles from the leading oncologic
journal, JCO. Since our current goal is to build a comprehensive
database of anticancer drug associated side effects, we biased our
approach toward achieving high recall. Our algorithm achieved
an overall precision of 0.405, a recall of 0.899, and an F1 score of
0.465. However, our approaches have limitations and can be
further improved upon.
First, while the recall (0.899) of our relationship approach was
high, the precision (0.465) could be further improved. We have
manually created two large-scale SE lexicons, which signiﬁcantly
improved the precision from 0.112 to 0.230. We then ﬁltered out
many false positives due to drug–disease treatment pairs and
further improved the precision from 0.230 to 0.405. The still
modest precision is mainly caused by the inclusion of drug–disease
co-occurrence pairs where the diseases are actually patient exclu-
sion criteria. In the future, we will develop text classiﬁcation
approaches to categorize paragraphs (or sections) in JCO articles
into toxicity-related or -unrelated before drug–SE relationship
extraction. In addition, the current database as well as the
automatically annotated or tagged text can serve as a pre-processing
step for manual drug safely annotation.
R. Xu, Q. Wang / Journal of Biomedical Informatics 55 (2015) 64–72 71Second, our knowledge base consisted of drug–SE pairs for
individual drugs. In reality, cancer drugs, including targeted cancer
drugs, are often used in combination with other drugs. Certain side
effects may only occur for speciﬁc drug–drug combinations.
Currently, the work on extracting side effects associated with
drug–drug combinations from free-text is scant. A recent study
led by Altman mined the FDA post-marketing FAERS database
and found four pairs of drugs that seemed to cause symptoms only
in combinations [37]. However, extracting side effects associated
with drug combinations from free text will be different from
mining patterns from the FAERS database.
Currently, we are integrating higher-level phenotypical drug
side effect data with lower-level drug-related datasets such as drug
targets, chemical structures, and gene expression as well as
disease-related data such as disease-associated genes and disease
phenotype data in order to develop systems approaches to drug
target discovery, drug toxicity prediction and drug repositioning.
6. Conclusions
We presented an automatic process in combining text
classiﬁcation, relationship extraction, signal ﬁltering and signal
ranking approaches to extract side effects associated with targeted
anticancer drugs from a large number of high proﬁle full-text
oncologic articles. Our extraction and ﬁltering algorithms achieved
a precision of 0.405, a recall of 0.899, and an F1 score of 0.465. This
targeted drug-speciﬁc toxicity knowledge base consisted of 26,264
drug–SE pairs with drugs linked to their known ‘‘on-targets’’ and
disease indications. We have shown that the toxicity knowledge
in this knowledge base is largely complementary to that contained
in FDA drug labeling. This unique toxicity knowledge base for
targeted cancer drugs could facilitate the development of
computational models to illuminate the complex pathways of
drug-induced toxicities that up until now have remained obscure.
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